Recommendations on the management of patients with axial spondyloarthritis
https://doi.org/10.29235/1814-6023-2019-16-1-117-128
Abstract
Spondyloarthritis is a group of diseases characterized by a primarily chronic, progressive inflammatory process with the affection of the axial skeleton (spine and sacroiliac joints) and peripheral joints having some common etiopathogenetic and clinical signs. The modern concept of spondyloarthritis involves the isolation of predominantly axial and predominantly peripheral variants of the disease. The problem of spondyloarthritis is in the center of attention of the medical community. Studies of the leading rheumatological centers are devoted to the aspects of the onset and development of the disease, therapy and prevention of disease progression. Signifcant progress has been made in the treatment of spondyloarthritis. The article contains the current recommendations on the management of patients with axial spondylitis.
About the Author
A. V. Kundzer
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Alena V. Kundzer – D. Sc. (Med.), Professor
3/3, P. Browka Str., 220013, Minsk
References
1. van der Heijde D., Ramiro S., Landewe R., Baraliakos X., Van den Bosch F., Sepriano A. [et al.]. 2016 update of ASASEULAR recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, vol. 76, pp. 978–991. https://doi.org/10.1136/annrheumdis-2016-210770
2. Vastesaeger N., Cruyssen B. V., Mulero J., Masmitjá J. G., Zarco P., Almodovar R., Font P., Juanola X., CollantesEstevez E. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF-therapy. Reumatología Clínica, 2014, vol. 10, no. 4, pp. 204–209. https://doi.org/10.1016/j.reumae.2013.12.025
3. Sieper J., Rudwaleit M., Baraliakos X., Brandt J., Braun J., Burgos-Vargas R. [et al.]. The Assessment of SponyloArthritis intrernational Society (ASAS) handbook: a guide to assess spondyloarthritis. Annals of the Rheumatic Diseases, 2009, vol. 68, suppl. 2, pp. ii1–ii44. https://doi.org/10.1136/ard.2008.104018
4. van der Heijde D., Lie E., Kvien T. K., Sieper J., van den Bosch F., Listing J., Braun J., Landewe R. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2008, vol. 68, no. 12, pp. 1811–1818. https://doi.org/10.1136/ard.2008.100826
5. Ramiro S., van der Heijde D., van Tubergen A., Stolwijk C., Dougados M., van den Bosch F., Landewé R. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Annals of the Rheumatic Diseases, 2014, vol. 73, no. 8, pp. 1455–1461. https://doi.org/10.1136/annrheumdis-2014-205178
6. Navarro-Compán V., Ramiro S., Landewé R., Dougados M., Miceli-Richard C., Richette P., van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Annals of the Rheumatic Diseases, 2015, vol. 75, no. 5, pp. 874–878. https://doi.org/10.1136/annrheumdis-2015-207786
7. Amor B. Data management in spondyloarthropathies. Rheumatology Europe, 1996, vol. 25, no. 3, pp. 92–95.
8. Poddubnyy D., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J., Rudwaleit M. Baseline radiographic damage, elevated acte-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis. Arthritis & Rheumatology, 2012, vol. 64, no. 5, pp. 1388–1398. https://doi.org/10.1002/art.33465
9. Sieper J., Lenaerts J., Wollenhaupt J., Rudwaleit M., Mazurov V. I., Myasoutova L., Park S., Song Y., Yao R., Chitkara D., Vastesaeger N. Effcacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Annals of the Rheumatic Diseases, 2013, vol. 73, no. 1, pp. 101–107. https://doi.org/10.1136/annrheumdis-2012-203201
10. Bakland G., Gran J. T., Nossent J. C. Increased mortality in ankylosing spondylitis is related to disease activity. Annals of the Rheumatic Diseases, 2011, vol. 70, no. 11, pp. 1921–1925. https://doi.org/10.1136/ard.2011.151191
11. Kroon F., Landewé R., Dougados M., van der Heijde D. Continuous nsaid use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, vol. 71, no. 10, pp. 1623–1629. https://doi.org/10.1136/annrheumdis-2012-201370
12. Poddubnyy D., Rudwaleit M., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J. Effect of nonsteroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from German spondyloarthritis inception cohort. Annals of the Rheumatic Diseases, 2012, vol. 71, no. 10, pp. 1616–1622. https://doi.org/10.1136/annrheumdis-2011-201252
13. Poddubnyy D., Rudwaleit M., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J. Effect of nonsteroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from German spondyloarthritis inception cohort. Annals of the Rheumatic Diseases, 2012, vol. 71, no. 10, pp. 1616–1622. https://doi.org/10.1136/annrheumdis-2011-201252
14. Haibel H., Fendler C., Listing J., Callhoff J., Braun J., Sieper J. Effcacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomized, placebo-conrtolled short-term trial. Annals of the Rheumatic Diseases, 2013, vol. 73, no. 1, pp. 243–246. https://doi.org/10.1136/annrheumdis-2012-203055
15. Chen J., Liu C. Sulfasalazin for ankylosing spondylitis. Cochrane Database of Systematic Reviews, 2006, vol. 2, p. CD004800.
16. Arends S., Brouwer E., van der Veer E., Groen H., Leijsma M. K., Houtman P. M., Jansen T. L. Th. A., Kallenberg C. G. M., Spoorenberg A. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Research & Therapy, 2011, vol. 13, no. 3, p. R94. https://doi.org/10.1186/ar3369
17. Sepriano A., Rudwaleit M., Sieper J., van den Berg R., Landewé R., van der Heijde D.Five-year follow-up of radiographic sacroiliitis: progression as well as improvement? Annals of the Rheumatic Diseases, 2016, vol. 75, no. 6, pp. 1262–1263. https://doi.org/10.1136/annrheumdis-2015-208964
18. Sieper J., van der Heijde D., Dougados M., Mease P. J., Maksymowych W. P., Brown M. A., Arora V., Pangan A. L. Effcacy and safety of adalimumab in patients with non-radiographic sxisl spondyloarthritis: results of randomised placebоcontrolled trial (ABILITY-1). Annals of the Rheumatic Diseases, 2012, vol. 72, no. 6, pp. 815–822. https://doi.org/10.1136/annrheumdis-2012-201766
19. Sieper J., van der Heijde D., Dougados M., Maksymowych W. P., Scott B. B., Boice J. A. [et al.]. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis and Rheumatology, 2015, vol. 67, no. 10, pp. 2702–2712. https://doi.org/10.1002/art.39257
20. Landewe R., Deodhar J. A., Dougados M., Maksymowych W. P., Mease P. J., Reveille J. D. [et al.]. Effcacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a doubleblind randomized placebo-controlled phase 3 study. Annals of the Rheumatic Diseases, 2013, vol. 73, no. 1, pp. 39–47. https://doi.org/10.1136/annrheumdis-2013-204231
21. Braun J., Davis J., Dougados M., Sieper J., van der Linden S., van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2006, vol. 65, no. 3, pp. 316–320. https://doi.org/10.1136/ard.2005.040758
22. Machado P., Landewe R., Lie E., Kvien T. K., Braun J., Baker D., van der Heijde D. Ankylosing Spondylitis Disease Activity score (ASDAS): defning cut-off values for disease activity states and improvement scoreas. Annals of the Rheumatic Diseases, 2010, no. 1, vol. 70, pp. 47–53. https://doi.org/10.1136/ard.2010.138594
23. Smolen J. S., Landewe R., Bijsma J., Burmester G., Chatzidionysiou K., Dougados M. [et al.]. EULAR recommendations for the mahagement of rheumatoid arthritis with synthetic and biological disease-modifying drugs: 2013 update. Annals of the Rheumatic Diseases, 2014, vol. 73, pp. 492–509.
24. Hueber W., Sands B. E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P. D. [et al.]. Secukinumab in Crohn’s Disease Study Group. Sekukinumab, a human anti-IL A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind placebo-controlled trial. Gut, 2012, vol. 61, pp. 1693–1700.
25. Langley R. G., Elewski B.E., Lebwohl M., Reich K., Griffths C.E., Papp K. [et al.]. ERASURE Study Sekukinumab in plaque psoriasis-results of two phase 3 trials. New England Journal of Medicine, 2014, vol. 371, pp. 326–338.
26. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut, 2007, vol. 56, no. 9, pp. 1232–1239. https://doi.org/10.1136/gut.2006.106781
27. van Denderen J. C., Visman I. M., Nurmohamed M. T., Suttorp-Schulten M. S. A., van der Horst-Bruinsma I. E. Adalimumab signifcantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. Journal of Rheumatology, 2014, vol. 41, no. 9, pp. 1843–1848. https://doi.org/10.3899/jrheum.131289
28. Gosses L., Smolen J.S., Ramiro S., de Wit M., Cutolo M., Dougados M. [et al.]. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 2016, vol. 75, pp. 499–510.
29. Lie E., van der Heijde D., Uhlig T., Mikkelsen K., Rodevand E., Koldingsnes W., Kaufmann C., Kvien T. K. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis data from the NOR-DMARD register. Annals of the Rheumatic Diseases, 2010, vol. 70, no. 1, pp. 157–163. https://doi.org/10.1136/ard.2010.131797
30. Sieper J., Listing J., Poddubnyy D., Song I.-H., Hermann K.-G., Callhoff J., Syrbe U., Braun J., Rudwaleit M. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomized multicenter trial (ENRADAS). Annals of the Rheumatic Diseases, 2015, vol. 75, no. 8, pp. 1438–1443. https://doi.org/10.1136/annrheumdis-2015-207897
31. Cantini F., Laura N., Kaloudi C., Carlotta N. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective. Long-term, follow-up study. Biologics, 2013, vol. 7, pp. 1–6. https://doi.org/10.2147/btt.s31474
32. Song I. H., Althoff C. E., Haibel H., Hermann K.-G. A., Poddubnyy D., Listing J. [et al.]. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis; 2 year data of the ESTHER trial. Annals of the Rheumatic Diseases, 2012, vol. 71, no. 7, pp. 1212–1215. https://doi.org/10.1136/annrheumdis-2011-201010
33. Vander Cruyssen B., Muñoz-Gomariz E., Font P., Mulero J., de Vlam K., Boonen A., Vazquez-Mellado J., Flores D., Vastesaeger N., Collantes E. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford), 2009, vol. 49, no. 1, pp. 73–81. https://doi.org/10.1093/rheumatology/kep174
34. van Royen B. J., de Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structed review of three methods of treatment. Annals of the Rheumatic Diseases, 1999, vol. 58, no. 7, pp. 399–406. https://doi.org/10.1136/ard.58.7.399
35. Westerveld L. A., Verlaan J. J., Oner F. C. Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications. European Spine Journal, 2008, vol. 18, no. 2, pp. 145–156. https://doi.org/10.1007/s00586-008-0764-0
Review
For citations:
Kundzer A.V. Recommendations on the management of patients with axial spondyloarthritis. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2019;16(1):117-128. (In Russ.) https://doi.org/10.29235/1814-6023-2019-16-1-117-128
Views: 840
Email this article 